Cargando…
Structural Basis of Metallo-β-lactamase Inhibition by N-Sulfamoylpyrrole-2-carboxylates
[Image: see text] Metallo-β-lactamases (MBLs) can efficiently catalyze the hydrolysis of all classes of β-lactam antibiotics except monobactams. While serine-β-lactamase (SBL) inhibitors (e.g., clavulanic acid, avibactam) are established for clinical use, no such MBL inhibitors are available. We rep...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205225/ https://www.ncbi.nlm.nih.gov/pubmed/34003651 http://dx.doi.org/10.1021/acsinfecdis.1c00104 |
_version_ | 1783708468524351488 |
---|---|
author | Farley, Alistair J. M. Ermolovich, Yuri Calvopiña, Karina Rabe, Patrick Panduwawala, Tharindi Brem, Jürgen Björkling, Fredrik Schofield, Christopher J. |
author_facet | Farley, Alistair J. M. Ermolovich, Yuri Calvopiña, Karina Rabe, Patrick Panduwawala, Tharindi Brem, Jürgen Björkling, Fredrik Schofield, Christopher J. |
author_sort | Farley, Alistair J. M. |
collection | PubMed |
description | [Image: see text] Metallo-β-lactamases (MBLs) can efficiently catalyze the hydrolysis of all classes of β-lactam antibiotics except monobactams. While serine-β-lactamase (SBL) inhibitors (e.g., clavulanic acid, avibactam) are established for clinical use, no such MBL inhibitors are available. We report on the synthesis and mechanism of inhibition of N-sulfamoylpyrrole-2-carboxylates (NSPCs) which are potent inhibitors of clinically relevant B1 subclass MBLs, including NDM-1. Crystallography reveals that the N-sulfamoyl NH(2) group displaces the dizinc bridging hydroxide/water of the B1 MBLs. Comparison of crystal structures of an NSPC and taniborbactam (VRNX-5133), presently in Phase III clinical trials, shows similar binding modes for the NSPC and the cyclic boronate ring systems. The presence of an NSPC restores meropenem efficacy in clinically derived E. coli and K. pneumoniae blaNDM-1. The results support the potential of NSPCs and related compounds as efficient MBL inhibitors, though further optimization is required for their clinical development. |
format | Online Article Text |
id | pubmed-8205225 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Chemical
Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-82052252021-06-16 Structural Basis of Metallo-β-lactamase Inhibition by N-Sulfamoylpyrrole-2-carboxylates Farley, Alistair J. M. Ermolovich, Yuri Calvopiña, Karina Rabe, Patrick Panduwawala, Tharindi Brem, Jürgen Björkling, Fredrik Schofield, Christopher J. ACS Infect Dis [Image: see text] Metallo-β-lactamases (MBLs) can efficiently catalyze the hydrolysis of all classes of β-lactam antibiotics except monobactams. While serine-β-lactamase (SBL) inhibitors (e.g., clavulanic acid, avibactam) are established for clinical use, no such MBL inhibitors are available. We report on the synthesis and mechanism of inhibition of N-sulfamoylpyrrole-2-carboxylates (NSPCs) which are potent inhibitors of clinically relevant B1 subclass MBLs, including NDM-1. Crystallography reveals that the N-sulfamoyl NH(2) group displaces the dizinc bridging hydroxide/water of the B1 MBLs. Comparison of crystal structures of an NSPC and taniborbactam (VRNX-5133), presently in Phase III clinical trials, shows similar binding modes for the NSPC and the cyclic boronate ring systems. The presence of an NSPC restores meropenem efficacy in clinically derived E. coli and K. pneumoniae blaNDM-1. The results support the potential of NSPCs and related compounds as efficient MBL inhibitors, though further optimization is required for their clinical development. American Chemical Society 2021-05-18 2021-06-11 /pmc/articles/PMC8205225/ /pubmed/34003651 http://dx.doi.org/10.1021/acsinfecdis.1c00104 Text en © 2021 The Authors. Published by American Chemical Society Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Farley, Alistair J. M. Ermolovich, Yuri Calvopiña, Karina Rabe, Patrick Panduwawala, Tharindi Brem, Jürgen Björkling, Fredrik Schofield, Christopher J. Structural Basis of Metallo-β-lactamase Inhibition by N-Sulfamoylpyrrole-2-carboxylates |
title | Structural Basis of Metallo-β-lactamase Inhibition
by N-Sulfamoylpyrrole-2-carboxylates |
title_full | Structural Basis of Metallo-β-lactamase Inhibition
by N-Sulfamoylpyrrole-2-carboxylates |
title_fullStr | Structural Basis of Metallo-β-lactamase Inhibition
by N-Sulfamoylpyrrole-2-carboxylates |
title_full_unstemmed | Structural Basis of Metallo-β-lactamase Inhibition
by N-Sulfamoylpyrrole-2-carboxylates |
title_short | Structural Basis of Metallo-β-lactamase Inhibition
by N-Sulfamoylpyrrole-2-carboxylates |
title_sort | structural basis of metallo-β-lactamase inhibition
by n-sulfamoylpyrrole-2-carboxylates |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205225/ https://www.ncbi.nlm.nih.gov/pubmed/34003651 http://dx.doi.org/10.1021/acsinfecdis.1c00104 |
work_keys_str_mv | AT farleyalistairjm structuralbasisofmetalloblactamaseinhibitionbynsulfamoylpyrrole2carboxylates AT ermolovichyuri structuralbasisofmetalloblactamaseinhibitionbynsulfamoylpyrrole2carboxylates AT calvopinakarina structuralbasisofmetalloblactamaseinhibitionbynsulfamoylpyrrole2carboxylates AT rabepatrick structuralbasisofmetalloblactamaseinhibitionbynsulfamoylpyrrole2carboxylates AT panduwawalatharindi structuralbasisofmetalloblactamaseinhibitionbynsulfamoylpyrrole2carboxylates AT bremjurgen structuralbasisofmetalloblactamaseinhibitionbynsulfamoylpyrrole2carboxylates AT bjorklingfredrik structuralbasisofmetalloblactamaseinhibitionbynsulfamoylpyrrole2carboxylates AT schofieldchristopherj structuralbasisofmetalloblactamaseinhibitionbynsulfamoylpyrrole2carboxylates |